Seplat Lowers 2026 Capex Guidance to $280M-$340M
Seplat lowered its 2026 capital expenditure guidance to $280 million-$340 million.
Related stories
BrightSpring Q3 Adjusted EBITDA Rises 42% to $227.76 Million
BrightSpring reported Q3 2026 adjusted EBITDA of $227.76 million, up 42% year over year.
M impact | EARNINGS | Oct 30, 2026, 10:05 AM UTC
BP earnings above expectations at 0.54 USD
BP (BP) released earnings per share at 0.54 USD, compared to market expectations of 0.23 USD.
H impact | EARNINGS | Oct 30, 2026, 10:02 AM UTC
AstraZeneca Reports 7% Nine-Month Revenue Growth, Reiterates FY26 Guidance
Revenue for the nine months ended September 30 rose 7% to $46.88 billion. Reported EPS increased 10% to $5.62, while operating profit rose 10% to $11.80 billion and underlying earn
M impact | EARNINGS | Oct 30, 2026, 09:58 AM UTC
SCOR’s Third-Quarter Net Profit Falls Less Than Expected
M impact | EARNINGS | Oct 30, 2026, 09:45 AM UTC
Sun Pharma Profit Falls on Costs Tied to Organon Deal
Sun Pharma said profit fell due to expenses related to its Organon transaction, while specialty drug sales remained solid.
M impact | EARNINGS | Oct 30, 2026, 09:19 AM UTC
Magna Beats Q3 Adjusted EPS Estimates, Raises FY Free-Cash-Flow Forecast
Magna reported Q3 adjusted EPS above estimates and raised its full-year free-cash-flow forecast.
M impact | EARNINGS | Oct 30, 2026, 09:13 AM UTC